The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
| Autor: | Suhong Xie, Bing Xiu, Weizhe Qiu, Suxia Zhang, Xianghua Yi, Xia Fang, Long Zhang, Xuyou Zhu, Aibin Liang, Xue Chen, Yu Zeng, Yunjin Wu, Zhi-Zhang Yang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Programmed Cell Death 1 Receptor Chromosomal translocation Kaplan-Meier Estimate Severity of Illness Index B7-H1 Antigen Tumor Protein 63 0302 clinical medicine hemic and lymphatic diseases Regulation of gene expression Aged 80 and over biology Age Factors General Medicine Middle Aged Prognosis Gene Expression Regulation Neoplastic Survival Rate Treatment Outcome programmed cell death 1 030220 oncology & carcinogenesis ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Female Lymphoma Large B-Cell Diffuse TP63 Research Article Adult China diffuse large B-cell lymphoma Observational Study 03 medical and health sciences Lymphocytes Tumor-Infiltrating Asian People PD-L1 medicine Biomarkers Tumor Humans Aged Neoplasm Staging Proportional Hazards Models Chi-Square Distribution Cluster of differentiation business.industry Tumor Suppressor Proteins RNA programmed cell death ligand 1 medicine.disease Lymphoma 030104 developmental biology Cancer research biology.protein business Diffuse large B-cell lymphoma Transcription Factors |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | Supplemental Digital Content is available in the text Latest study showed that a novel translocation between programmed cell death ligand 1 (PD-L1) (cluster of differentiation 274) and TP63 (tumor protein 63) can be found in diffuse large B-cell lymphoma (DLBCL), resulting in their conjunct overexpression in tumor cells at RNA level. However, the expressed pattern of these 2 genes at protein level in DLBCL remains largely unknown, and the clinical relevance of PD-L1 and TP63 expression in DLBCL are also unclear. Tumor tissues from 76 Chinese DLBCL patients were immunostained for programmed cell death 1 (PD-1), PD-L1, and TP63 using the EnVision system. Clinical relevance of PD-1, PD-L1, and TP63 in 74 DLBCL were analyzed by chi-square test, the Kaplan–Meier curves with log rank test, and Cox's proportional hazards regression model. PD-1 was mainly expressed in tumor-infiltrating lymphocytes (TILs) of 39.5% patients. PD-L1 was expressed in tumor cells of 26.3% patients, and TP63 was immunostained in nucleoli of tumor cells of 31.6% cases. PD-1 expression was significantly associated with the patients’ gender and B symptoms (P = 0.032, P = 0.026). DLBCL with PD-L1 or TP63 expression in tumor cells showed low International Prognostic Index (IPI) score (P = 0.007, P = 0.009). PD-1+ TILs was related to prolonged overall survival rate (OS) of DLBCL patients (P = 0.02), whereas PD-L1 expression was associated with worse clinical outcome of patients (P = 0.049). Immunoreactivity of TP63 was not correlated with patients’ survival time. Besides, PD-1 expression, patients’ age, Ann Arbor stage, and IPI score were significant prognostic markers for OS, but PD-L1 and TP63 had no prognostic significance. PD-1, PD-L1, and TP63 are frequently expressed in DLBCL. PD-1/PD-L1/TP63 blockade may be a potential therapeutic strategy for some patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|